(Sharecast News) - Shares in Galderma Group sagged on Wednesday, after the US Food and Drug Administration rejected the Swiss firm's Botox rival.
The dermatology specialist is seeking a biologics license from the American regulator for relabotulinumtoxinA, which is already approved under the brand name Relfydess in 33 markets.

In...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE